This HTML5 document contains 242 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/pubchem-substance/
n28http://linked.opendata.cz/resource/AHFS/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n24http://linked.opendata.cz/resource/drugbank/dosage/
n9http://linked.opendata.cz/resource/drugbank/mixture/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/national-drug-code-directory/
n23http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n25http://linked.opendata.cz/resource/drugbank/patent/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/chebi/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/wikipedia/
n3http://linked.opendata.cz/ontology/drugbank/
n27http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/pharmgkb/
n29http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00443/identifier/pubchem-compound/
n7http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00443
rdf:type
n3:Drug
n3:description
A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
n3:dosage
n24:271B50A0-363D-11E5-9242-09173F13E4C5 n24:271B50A1-363D-11E5-9242-09173F13E4C5 n24:271B509C-363D-11E5-9242-09173F13E4C5 n24:271B509D-363D-11E5-9242-09173F13E4C5 n24:271B509E-363D-11E5-9242-09173F13E4C5 n24:271B509F-363D-11E5-9242-09173F13E4C5 n24:271B5098-363D-11E5-9242-09173F13E4C5 n24:271B5099-363D-11E5-9242-09173F13E4C5 n24:271B509A-363D-11E5-9242-09173F13E4C5 n24:271B509B-363D-11E5-9242-09173F13E4C5 n24:271B5094-363D-11E5-9242-09173F13E4C5 n24:271B5095-363D-11E5-9242-09173F13E4C5 n24:271B5096-363D-11E5-9242-09173F13E4C5 n24:271B5097-363D-11E5-9242-09173F13E4C5 n24:271B5090-363D-11E5-9242-09173F13E4C5 n24:271B5091-363D-11E5-9242-09173F13E4C5 n24:271B5092-363D-11E5-9242-09173F13E4C5 n24:271B5093-363D-11E5-9242-09173F13E4C5 n24:271B508F-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
5.6 hours
n3:indication
<b>Topical use (cream, lotion and ointment):</b> for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses<br/><b>Topical use (foam):</b> relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp<br/><b>Systemic use:</b> for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis.
n3:manufacturer
n5:271B503B-363D-11E5-9242-09173F13E4C5 n5:271B503C-363D-11E5-9242-09173F13E4C5 n5:271B5039-363D-11E5-9242-09173F13E4C5 n5:271B503A-363D-11E5-9242-09173F13E4C5 n5:271B503F-363D-11E5-9242-09173F13E4C5 n5:271B5040-363D-11E5-9242-09173F13E4C5 n5:271B503D-363D-11E5-9242-09173F13E4C5 n5:271B503E-363D-11E5-9242-09173F13E4C5 n5:271B5036-363D-11E5-9242-09173F13E4C5 n5:271B5037-363D-11E5-9242-09173F13E4C5 n5:271B5035-363D-11E5-9242-09173F13E4C5 n5:271B5038-363D-11E5-9242-09173F13E4C5 n5:271B5049-363D-11E5-9242-09173F13E4C5 n5:271B504A-363D-11E5-9242-09173F13E4C5 n5:271B5043-363D-11E5-9242-09173F13E4C5 n5:271B5044-363D-11E5-9242-09173F13E4C5 n5:271B5041-363D-11E5-9242-09173F13E4C5 n5:271B5042-363D-11E5-9242-09173F13E4C5 n5:271B5047-363D-11E5-9242-09173F13E4C5 n5:271B5048-363D-11E5-9242-09173F13E4C5 n5:271B5045-363D-11E5-9242-09173F13E4C5 n5:271B5046-363D-11E5-9242-09173F13E4C5
owl:sameAs
n19:DB00443 n23:DB00443
dcterms:title
Betamethasone
adms:identifier
n11:D00244 n12:9399 n13:DB00443 n14:9782 n15:46505155 n16:0085-0942-05 n17:3077 n20:Betamethasone n21:PA164754818
n3:mechanismOfAction
Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.
n3:packager
n5:271B5033-363D-11E5-9242-09173F13E4C5 n5:271B5030-363D-11E5-9242-09173F13E4C5 n5:271B5031-363D-11E5-9242-09173F13E4C5 n5:271B502E-363D-11E5-9242-09173F13E4C5 n5:271B502F-363D-11E5-9242-09173F13E4C5 n5:271B502C-363D-11E5-9242-09173F13E4C5 n5:271B502D-363D-11E5-9242-09173F13E4C5 n5:271B5020-363D-11E5-9242-09173F13E4C5 n5:271B5021-363D-11E5-9242-09173F13E4C5 n5:271B501E-363D-11E5-9242-09173F13E4C5 n5:271B501F-363D-11E5-9242-09173F13E4C5 n5:271B501C-363D-11E5-9242-09173F13E4C5 n5:271B501D-363D-11E5-9242-09173F13E4C5 n5:271B501A-363D-11E5-9242-09173F13E4C5 n5:271B501B-363D-11E5-9242-09173F13E4C5 n5:271B5019-363D-11E5-9242-09173F13E4C5 n5:271B500F-363D-11E5-9242-09173F13E4C5 n5:271B5010-363D-11E5-9242-09173F13E4C5 n5:271B500D-363D-11E5-9242-09173F13E4C5 n5:271B500E-363D-11E5-9242-09173F13E4C5 n5:271B500B-363D-11E5-9242-09173F13E4C5 n5:271B500C-363D-11E5-9242-09173F13E4C5 n5:271B5009-363D-11E5-9242-09173F13E4C5 n5:271B500A-363D-11E5-9242-09173F13E4C5 n5:271B5017-363D-11E5-9242-09173F13E4C5 n5:271B5018-363D-11E5-9242-09173F13E4C5 n5:271B5022-363D-11E5-9242-09173F13E4C5 n5:271B5015-363D-11E5-9242-09173F13E4C5 n5:271B5023-363D-11E5-9242-09173F13E4C5 n5:271B5016-363D-11E5-9242-09173F13E4C5 n5:271B5013-363D-11E5-9242-09173F13E4C5 n5:271B5014-363D-11E5-9242-09173F13E4C5 n5:271B5011-363D-11E5-9242-09173F13E4C5 n5:271B5012-363D-11E5-9242-09173F13E4C5 n5:271B5034-363D-11E5-9242-09173F13E4C5 n5:271B502A-363D-11E5-9242-09173F13E4C5 n5:271B502B-363D-11E5-9242-09173F13E4C5 n5:271B5028-363D-11E5-9242-09173F13E4C5 n5:271B5029-363D-11E5-9242-09173F13E4C5 n5:271B5026-363D-11E5-9242-09173F13E4C5 n5:271B5027-363D-11E5-9242-09173F13E4C5 n5:271B5024-363D-11E5-9242-09173F13E4C5 n5:271B5025-363D-11E5-9242-09173F13E4C5 n5:271B5032-363D-11E5-9242-09173F13E4C5
n3:patent
n25:7078058 n25:6126920
n3:synonym
beta-Methasone alcohol 9-Fluoro-16β-methylprednisolone Betamethasonvalerat Mikron 16β-Methyl-1,4-pregnadiene-9α-fluoro-11β,17α,21-triol-3,20-dione 9alpha-Fluoro-16beta-methylprednisolone Betamethasone Betamethasonum Betadexamethasone 9-Fluoro-16beta-methylprednisolone 9α-Fluoro-16β-methylprednisolone Rinderon Betametasona 16beta-Methyl-1,4-pregnadiene-9alpha-fluoro-11beta,17alpha,21-triol-3,20-dione
n3:toxicity
Symptoms of overdose include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
n6:hasAHFSCode
n28:84-06-00
n3:foodInteraction
Take with food to reduce irritation.
n3:mixture
n9:271B5008-363D-11E5-9242-09173F13E4C5 n9:271B5006-363D-11E5-9242-09173F13E4C5 n9:271B5007-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
64%
n3:salt
n3:synthesisReference
Fernando AHUMADA AYALA, "SKIN-CARE PREPARATIONS CONTAINING MUPIROCIN AND BETAMETHASONE DIPROPIONATE." U.S. Patent US20100063015, issued March 11, 2010.
foaf:page
n27:betamethasone.html n29:betamet.htm
n3:IUPAC-Name
n4:271B50A6-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B50AC-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B50AB-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B50A8-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B50A9-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B50AA-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B50A4-363D-11E5-9242-09173F13E4C5 n4:271B50BC-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B50A2-363D-11E5-9242-09173F13E4C5 n4:271B50A5-363D-11E5-9242-09173F13E4C5 n4:271B50BE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B50A3-363D-11E5-9242-09173F13E4C5 n4:271B50BF-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:C05AA05 n7:D07AC01 n7:A07EA04 n7:R03BA04 n7:S03BA03 n7:S01BA06 n7:H02AB01 n7:S02BA07 n7:D07XC01 n7:S01CB04 n7:R01AD06
n3:H-Bond-Acceptor-Count
n4:271B50B2-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B50B3-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B50AD-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B50AE-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B50B0-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B50AF-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B50B1-363D-11E5-9242-09173F13E4C5
n3:absorption
Minimal if applied topically.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
378-44-9
n3:category
n3:containedIn
n8:271B5086-363D-11E5-9242-09173F13E4C5 n8:271B5087-363D-11E5-9242-09173F13E4C5 n8:271B5084-363D-11E5-9242-09173F13E4C5 n8:271B5085-363D-11E5-9242-09173F13E4C5 n8:271B5082-363D-11E5-9242-09173F13E4C5 n8:271B5083-363D-11E5-9242-09173F13E4C5 n8:271B5080-363D-11E5-9242-09173F13E4C5 n8:271B5081-363D-11E5-9242-09173F13E4C5 n8:271B508D-363D-11E5-9242-09173F13E4C5 n8:271B508E-363D-11E5-9242-09173F13E4C5 n8:271B508A-363D-11E5-9242-09173F13E4C5 n8:271B508C-363D-11E5-9242-09173F13E4C5 n8:271B5088-363D-11E5-9242-09173F13E4C5 n8:271B5089-363D-11E5-9242-09173F13E4C5 n8:271B5056-363D-11E5-9242-09173F13E4C5 n8:271B5057-363D-11E5-9242-09173F13E4C5 n8:271B5054-363D-11E5-9242-09173F13E4C5 n8:271B5055-363D-11E5-9242-09173F13E4C5 n8:271B5052-363D-11E5-9242-09173F13E4C5 n8:271B5053-363D-11E5-9242-09173F13E4C5 n8:271B5050-363D-11E5-9242-09173F13E4C5 n8:271B5051-363D-11E5-9242-09173F13E4C5 n8:271B505E-363D-11E5-9242-09173F13E4C5 n8:271B505F-363D-11E5-9242-09173F13E4C5 n8:271B505C-363D-11E5-9242-09173F13E4C5 n8:271B505D-363D-11E5-9242-09173F13E4C5 n8:271B505A-363D-11E5-9242-09173F13E4C5 n8:271B505B-363D-11E5-9242-09173F13E4C5 n8:271B5058-363D-11E5-9242-09173F13E4C5 n8:271B5059-363D-11E5-9242-09173F13E4C5 n8:271B504D-363D-11E5-9242-09173F13E4C5 n8:271B504F-363D-11E5-9242-09173F13E4C5 n8:271B504B-363D-11E5-9242-09173F13E4C5 n8:271B504C-363D-11E5-9242-09173F13E4C5 n8:271B5076-363D-11E5-9242-09173F13E4C5 n8:271B5077-363D-11E5-9242-09173F13E4C5 n8:271B5074-363D-11E5-9242-09173F13E4C5 n8:271B5075-363D-11E5-9242-09173F13E4C5 n8:271B5072-363D-11E5-9242-09173F13E4C5 n8:271B5073-363D-11E5-9242-09173F13E4C5 n8:271B5070-363D-11E5-9242-09173F13E4C5 n8:271B5071-363D-11E5-9242-09173F13E4C5 n8:271B507E-363D-11E5-9242-09173F13E4C5 n8:271B507F-363D-11E5-9242-09173F13E4C5 n8:271B507C-363D-11E5-9242-09173F13E4C5 n8:271B507D-363D-11E5-9242-09173F13E4C5 n8:271B507A-363D-11E5-9242-09173F13E4C5 n8:271B507B-363D-11E5-9242-09173F13E4C5 n8:271B5078-363D-11E5-9242-09173F13E4C5 n8:271B5079-363D-11E5-9242-09173F13E4C5 n8:271B5066-363D-11E5-9242-09173F13E4C5 n8:271B5067-363D-11E5-9242-09173F13E4C5 n8:271B5064-363D-11E5-9242-09173F13E4C5 n8:271B5065-363D-11E5-9242-09173F13E4C5 n8:271B5062-363D-11E5-9242-09173F13E4C5 n8:271B5063-363D-11E5-9242-09173F13E4C5 n8:271B5060-363D-11E5-9242-09173F13E4C5 n8:271B5061-363D-11E5-9242-09173F13E4C5 n8:271B506E-363D-11E5-9242-09173F13E4C5 n8:271B506F-363D-11E5-9242-09173F13E4C5 n8:271B506C-363D-11E5-9242-09173F13E4C5 n8:271B506D-363D-11E5-9242-09173F13E4C5 n8:271B506A-363D-11E5-9242-09173F13E4C5 n8:271B506B-363D-11E5-9242-09173F13E4C5 n8:271B5068-363D-11E5-9242-09173F13E4C5 n8:271B5069-363D-11E5-9242-09173F13E4C5 n8:271B508B-363D-11E5-9242-09173F13E4C5 n8:271B504E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B50B8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B50BA-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B50BB-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B50BD-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B50B7-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B50B6-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B50B9-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B50A7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B50B4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B50B5-363D-11E5-9242-09173F13E4C5